Nigrostriatal degeneration and serum BDNF levels in patients with “de novo” untreated Parkinson’s disease
Objective: To evaluate serum Brain-Derived NeurotrophicFactor(BDNF) levels in “de novo” untreated Parkinson's disease (PD) patients and their relationship to nigrostriatal degeneration measured with [123I]FP-CIT SPECT.…Levodopa induced dyskinesia and nicotinergic α4β2 acetylcholin receptor density: A multi-tracer imaging study
Objective: We investigated α4β2 acetylcholin receptor (nAChR) density in subjects with Parkinson's disease (PD) with and without levodopa-induced dyskinesia (LID) and its correlation with dopaminergic…Visual vs. automated analysis of [123I]FP-CIT SPECT scans in patients with parkinsonism
Objective: To investigate the differences between visual and automated analyses of brain dopamine transporter (DAT) SPECT scans. Background: Clinical evaluation of DAT SPECT scans typically…Comparison of DAT scan, cardiac MIBG scintigraphy, and cerebrospinal fluid 5HIAA levels in Parkinsonian syndrome
Objective: To assess the associations of presynaptic dopamine transporter (DAT scan), cardiac 123I-meta-iodobenzylguanidine (MIBG) scintigraphy, and cerebrospinal fluid (CSF) levels of 5-hydroxyindole acetic acid (5HIAA)…The efficacy of quantitative 99mTc-TRODAT-1 SPECT in diagnosis of aged patients with Parkinson’s disease
Objective: We aim to establish the normal reference with quantitative 99mTc-Trodat-1 (TRODAT) SPECT and verify the diagnostic performance in aged Parkinson's disease (PD) patients. Background:…Targeted over-expression with AAV-mediated human α-synuclein in a rat model of Parkinson’s disease – Validation of novel fine motor functional effects
Objective: Targeted over-expression of human α-synuclein using viral-vector mediated gene delivery into the substantia nigra of rats and non-human primates has been reported to lead…
- « Previous Page
- 1
- …
- 12
- 13
- 14